# Four-period Crossover Study to Assess the Effects of Single Oral Doses of ZD4054 (Zibotentan) (10mg and 30mg) on QTc Interval

> **NCT00713336** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 40 (estimated)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** ZD4054
- **DRUG:** Moxifloxacin
- **DRUG:** ZD4054 Placebo
- **DRUG:** Moxifloxacin placebo
- **DRUG:** ZD4054 Placebo
- **DRUG:** ZD4054
- **DRUG:** ZD4054

## Key facts

- **NCT ID:** NCT00713336
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** —
- **Final completion:** 2008-11
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2010-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00713336

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00713336, "Four-period Crossover Study to Assess the Effects of Single Oral Doses of ZD4054 (Zibotentan) (10mg and 30mg) on QTc Interval". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00713336. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*